BRD2 and neoplasm: Furthermore, by both immunoblot and IHC analysis, wildtype A3A protein expression is already absent from tumor masses with the exception of rare A3A-expressing lesional cells and heterogeneous in NAT hepatocytes (i.e., A3A is already selected against, Figure 3C,D).